Critical Review: Journey Medical (DERM) versus The Competition

Journey Medical (NASDAQ:DERMGet Free Report) is one of 981 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its peers? We will compare Journey Medical to related businesses based on the strength of its dividends, valuation, earnings, analyst recommendations, profitability, institutional ownership and risk.

Analyst Ratings

This is a summary of current recommendations and price targets for Journey Medical and its peers, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Journey Medical 0 0 1 0 3.00
Journey Medical Competitors 6008 17944 42568 858 2.57

Journey Medical currently has a consensus price target of $8.50, suggesting a potential upside of 149.27%. As a group, “Pharmaceutical preparations” companies have a potential upside of 68.85%. Given Journey Medical’s stronger consensus rating and higher possible upside, analysts clearly believe Journey Medical is more favorable than its peers.

Earnings and Valuation

This table compares Journey Medical and its peers revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Journey Medical $73.67 million -$29.63 million -4.11
Journey Medical Competitors $2.11 billion $157.53 million -4.00

Journey Medical’s peers have higher revenue and earnings than Journey Medical. Journey Medical is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

9.0% of Journey Medical shares are held by institutional investors. Comparatively, 39.4% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 19.4% of Journey Medical shares are held by insiders. Comparatively, 14.5% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.


This table compares Journey Medical and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Journey Medical -15.46% -118.05% -14.68%
Journey Medical Competitors -2,256.71% -226.51% -30.53%

Risk & Volatility

Journey Medical has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. Comparatively, Journey Medical’s peers have a beta of 0.71, meaning that their average stock price is 29% less volatile than the S&P 500.


Journey Medical beats its peers on 8 of the 13 factors compared.

About Journey Medical

(Get Free Report)

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Zilxi, a topical minocycline treatment for inflammatory lesions; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.

Receive News & Ratings for Journey Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Journey Medical and related companies with's FREE daily email newsletter.